

姓名	王润玲	职称	教授	所在部门	药学院	研究方向	基于靶点的创新药物研究	
办公室	药学院A楼302	电话	13602030967	电子邮箱	wangrunling@tmu.edu.cn			
教育背景								
<p>1978年8月 1982年7月北京大学医学部，本科学历，学士学位。</p> <p>2003年8月 2006年7月天津大学，研究生学历，博士学位。</p> <p>2001年8月-2002年7月 瑞典乌普萨拉大学，有机化学系，高级访问学者。</p>								
工作经历								
<p>2015.5-至今 天津医科大学药学院，教授</p> <p>1999.10-2015.4 天津医科大学药学院，教授，副院长</p> <p>1994.10-1999.9 天津医科大学药学院，副教授</p> <p>1984.10-1994.9 天津医科大学药学院，讲师</p> <p>1982.7-1984.9 天津医科大学药学院，助教</p>								
研究成果（本人具有代表性的论著、论文及主持的科研项目）								
论著及编著	<p>药物化学（主编）清华大学出版社，第二版，2018.5</p> <p>药物化学（主编）清华大学出版社，第一版，2013.7</p> <p>药物化学（主编）医药科技出版社，第三版，2012.5，</p> <p>药学专业化学实验II（主编），人民卫生出版社，2008.7</p> <p>药物化学（参编），人民卫生出版社，第八版，2016.2</p> <p>药物化学（参编），人民卫生出版社，第七版，2011.8</p> <p>药物化学（参编），中国医药科技出版社，第二版，2011.2</p> <p>临床药物化学（参编），人民卫生出版社，2007.8</p> <p>现代药物设计学（参编），中国医药科技出版社，2006</p>							
论文	<p>1. Ma Yangchun, Yang WenYu, Zhou Liang, Li LiPeng, Wu JingWei, Li WeiYa, Du Shan, Ma Ying* & Wang RunLing*. Exploring the cause of the dual allosteric targeted inhibition attaching to allosteric sites enhancing SHP2 inhibition. [J]. <i>Molecular Diversity</i>, 2021. Doi: 10.1007/s11030-021-10286-4.</p> <p>2. Hao-Xin Li, Wen-Yu Yang, Li-Peng Li, Hui Zhou, Wei-Ya Li, Ying Ma*,</p>							

Run-Ling Wang*. Molecular dynamics study of CDC25B^{R492L} mutant causing the activity decrease of CDC25B. [J]. *Journal of Molecular Graphics and Modelling*. 2021; 109:

- synthesis, biological evaluation and molecular dynamics simulation. [J]. *Biochemical and biophysical research communications*. 2020; 526(1): 273-280.
12. Jingwei Wu, Huan Zhang, Guilong Zhao*, and **Runling Wang***. Allosteric inhibitors of SHP2: an updated patent review (2015-2020). [J]. *Current Medicinal Chemistry*. 2020; 27:1-17
 13. Wen-Shan Liu, Wen-Yan Jin, Liang Zhou, Xing-Hua Lu, Wei-Ya Li, Ying Ma* & **Run-Ling Wang***. Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation. [J]. *Journal of Computer-Aided Molecular Design*. 2019; 33(8):759-774.
 14. Wen-Shan Liu, Rui-Rui Wang, Ying-Zhan Sun, Wei-Ya Li, Hong-Lian Li, Chi-Lu Liu, Ying Ma*, **Run-Ling Wang***. Exploring the effect of inhibitor AKB-9778 on VE-PTP by molecular docking and molecular dynamics simulation. [J]. *Journal of Cellular Biochemistry*. 2019; 120(10): 17015-17029.
 15. Li Wei-Ya, Duan Yu-Qing, Ma Yang-Chun, Lu Xin-Hua, Ma Ying*, **Run-Ling Wang***. Exploring the cause of the inhibitor 4AX attaching to binding site disrupting protein tyrosine phosphatase 4A1 trimerization by molecular dynamic simulation. [J]. *Journal of Biomolecular Structure & Dynamics*. 2019; 37(18): 4840-4851.
 16. Yang-Chun Ma, Bing Yang, Xin Wang, Liang Zhou, Wei-Ya Li, Wen-Shan Liu, Xin-Hua Lu, Zhi-Hui Zheng, Ying Ma*, **Run-Ling Wang***. Identification of novel inhibitor of protein tyrosine phosphatases delta: structure-based pharmacophore modeling, virtual screening, flexible docking, molecular dynamics simulation, and post-molecular dynamics analysis. [J]. *J Biomol Struct Dyn*. 2019; 38(15): 4432-4448.
 17. Shan Du, Bing Yang, Xin Wang, Wei-Ya Li, Xin-Hua Lu, Zhi-Hui Zheng, Ying Ma*, **Run-Ling Wang***. Identification of potential leukocyte antigen-related protein (PTP-LAR) inhibitors through 3D QSAR pharmacophore-based virtual screening and molecular dynamics simulation. [J]. *J Biomol Struct Dyn*. 2019; 38(14): 4232-4245.
 18. Wen-Shan Liu, Rui-Rui Wang, Hai Yue, Zhi-Hui Zheng, Xin-Hua Lu, Shu-Qing Wang, Wei-Li Dong*, **Run-Ling Wang***. Design, synthesis, biological evaluation and molecular dynamics studies of 4-thiazolinone derivatives as Protein tyrosine phosphatase 1B (PTP1B) inhibitors. [J]. *J Biomol Struct Dyn*. 2019; 38(13): 3814-3824.
 19. Wen-Shan Liu, Rui-Rui Wang, Wei-Ya Li, Mei Rong, Chi-Lu Liu, Ying Ma*, **Run-Ling Wang***. Investigating the reason for loss-of-function of Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) caused by Y279C mutation through molecular dynamics simulation. [J]. *J Biomol Struct Dyn*. 2019; 38(9): 2509-2520.
 20. Rui-Rui Wang, Wen-Shan Liu, Liang Zhou, Ying Ma*, **Run-Ling Wang***. Probing the acting mode and advantages of RMC-4550 as an Src-homology 2 domain containing protein tyrosine phosphatase (SHP2) inhibitor at

- molecular Level through molecular docking and molecular dynamics. [J]. *J Biomol Struct Dyn*. 2019; 38(5): 1525-1538.
21. Rui-Rui Wang, Ying Ma, Shan Du, Wei-Ya Li, Ying-Zhan Sun, Hui Zhou, **Run-Ling Wang***. Exploring the reason for increased activity of SHP2 caused by D61Y mutation through molecular dynamics. [J]. *Computational Biology and Chemistry*. 2019; 78: 133-143.
 22. Ying-Zhan Sun, Jing-Wei Wu, Xin-Hua Lu, Ying Ma*, **Run-Ling Wang***. Exploring the effect of aplidin on low molecular weight protein tyrosine phosphatase by molecular docking and molecular dynamic simulation study. [J]. *Computational Biology and Chemistry*. 2019; 83: 107123.
 23. Jing-Wei Wu, Ling Yin, Yu-Qiang Liu, Huan Zhang, Ya-Fei Xie, **Run-Ling Wang***, Gui-Long Zhao*. Synthesis, biological evaluation and 3D-QSAR studies of 1,2,4-triazole-5-substituted carboxylic acid bioisosteres as uric acid transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia associated with gout. [J]. *Bioorganic & Medicinal Chemistry Letters*, 2019; 29(3): 383-388.
 24. Jingwei Wu, Yingzhan Sun, Hui Zhou, Ying Ma*, **Runling Wang***. Design, synthesis, biological evaluation and molecular dynamics simulation studies of (R)-5-methylthiazolidin-4-One derivatives as megakaryocyte protein tyrosine phosphatase 2 (PTP-MEG2) inhibitors for the treatment of type 2 diabetes. [J]. *Journal of Biomolecular Structure & Dynamics*. 2019; 38(11): 3156-3165.
 25. Liang Zhou, Yang-Chun Ma, Xue Tang, Wei-Ya Li, Ying Ma* & **Run-Ling Wang***, Identification of the potential dual inhibitor of protein tyrosine phosphatase sigma and leukocyte common antigen-related phosphatase by virtual screen, molecular dynamic simulations and postanalysis. [J]. *Journal of Biomolecular Structure & Dynamics*. 2019; 39(1): 45-62.
 26. Chen Li, Tan Xiao-li, ANTAL Rockenbauer, **Wang Run-ling**

